WINNIPEG, MANITOBA -- (MARKET WIRE) -- 05/05/2006 -- Medicure Inc. (TSX:MPH)(AMEX: MCU), a cardiovascular drug discovery and development company, today announced that it has entered into Securities Purchase Agreements (the “Agreements”) with U.S. and European institutional investors raising total gross proceeds of approximately US$25 million. Under terms of the Agreements, Medicure intends to issue approximately 16 million common shares at a price of US$1.60, together with warrants, to purchase approximately 4 million additional common shares. The warrants have a five year term and an exercise price of US$2.10. The private placement is expected to close in the next several days and is subject to the approval of the Toronto Stock Exchange and the American Stock Exchange and other customary closing conditions.